Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets
Travere Therapeutics, Inc. is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis+2New York Stock Exchange+2